Exelixis Stock Surges 7.43% to $43.77 on Positive Trial Data Becoming 202nd Most Traded Stock

On June 23, 2025, Exelixis (EXEL) saw a significant surge in its stock price, rising by 7.43% to close at $43.77, with a trading volume of $392 million, making it the 202nd most traded stock of the day.

Exelixis' stock price jumped following the release of positive phase 3 data for its experimental drug zanzalintinib in combination with Tecentriq. The data showed improved overall survival in patients with previously treated non-microsatellite instability colorectal cancer, marking a significant milestone for the company's pipeline.

The positive results from the STELLAR-303 phase 3 pivotal trial further bolstered investor confidence in Exelixis' pipeline. The trial demonstrated that zanzalintinib, when combined with an immune checkpoint inhibitor, improved overall survival in patients with colorectal cancer, a key indication for the drug.

Exelixis' stock has been on a strong upward trajectory, driven by the promising data from its clinical trials. The company's CABOMETYX sales growth of 36% and the potential market expansions for zanzalintinib have contributed to the positive sentiment surrounding the stock. Analysts have raised their 2025 guidance for Exelixis, citing the strong performance of its pipeline and the potential for zanzalintinib to become a significant revenue driver.